Tecentriq Placebo
Sponsors
F. Hoffmann-La Roche AG
Conditions
Early human epidermal growth factor receptor 2 (HER2) positive breast cancerEarly-Stage Resectable Non-small cell lung cancer (NSCLC)Unresectable Esophageal Squamous Cell Carcinoma
Phase 3
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients With resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
CompletedCTIS2023-504209-35-00
Start: 2018-04-04End: 2025-12-31Target: 207Updated: 2026-01-13
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY
Active, not recruitingCTIS2023-503568-18-00
Start: 2021-04-13Target: 377Updated: 2025-08-27
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have not Progressed following Definitive Concurrent Chemoradiotherapy
RecruitingCTIS2022-502052-30-00
Start: 2020-10-27Target: 167Updated: 2025-12-18